(Q44515995)

3 December 2017

Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open-label study (English)

1 reference

3 December 2017

1 reference

0 references

Chi Chiu Mok

1

1 reference

3 December 2017

Chak Sing Lau

series ordinal

2

1 reference

3 December 2017

Raymond W S Wong

series ordinal

3

1 reference

3 December 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

American Journal of Medicine

3 December 2017

1 reference

3 December 2017

115

1 reference

3 December 2017

1

1 reference

3 December 2017

59-62

1 reference

Lupus and the central nervous system

3 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900135-9

Neuropsychiatric syndromes in lupus: prevalence using standardized definitions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900135-9

Risk factors for central nervous system involvement in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900135-9

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900135-9

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900135-9

Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900135-9

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900135-9

Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900135-9

Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900135-9

Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900135-9

Cyclophosphamide pulse therapy in optic neuritis due to systemic lupus erythematosus: an open trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900135-9

Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900135-9

The 1982 revised criteria for the classification of systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900135-9

The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900135-9

Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900135-9

10.1016/S0002-9343(03)00135-9

7 January 2021

Identifiers

DOI

1 reference

3 December 2017

1 reference